+ Watch PCYC
on My Watchlist
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
Ibrutinib has potential, but risk reward is too unfavorable after the run up.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions